Success Metrics

Clinical Success Rate
92.0%

Based on 104 completed trials

Completion Rate
92%(104/113)
Active Trials
4(3%)
Results Posted
19%(20 trials)
Terminated
9(7%)

Phase Distribution

Ph phase_2
12
9%
Ph phase_4
34
27%
Ph phase_3
27
21%
Ph not_applicable
9
7%
Ph phase_1
30
24%

Phase Distribution

30

Early Stage

12

Mid Stage

61

Late Stage

Phase Distribution112 total trials
Phase 1Safety & dosage
30(26.8%)
Phase 2Efficacy & side effects
12(10.7%)
Phase 3Large-scale testing
27(24.1%)
Phase 4Post-market surveillance
34(30.4%)
N/ANon-phased studies
9(8.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.2%

104 of 114 finished

Non-Completion Rate

8.8%

10 ended early

Currently Active

4

trials recruiting

Total Trials

127

all time

Status Distribution
Active(6)
Completed(104)
Terminated(10)
Other(7)

Detailed Status

Completed104
Terminated9
unknown7
Recruiting4
Withdrawn1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
127
Active
4
Success Rate
92.0%
Most Advanced
Phase 4

Trials by Phase

Phase 130 (26.8%)
Phase 212 (10.7%)
Phase 327 (24.1%)
Phase 434 (30.4%)
N/A9 (8.0%)

Trials by Status

unknown76%
withdrawn11%
enrolling_by_invitation11%
completed10482%
not_yet_recruiting11%
terminated97%
recruiting43%

Recent Activity

Clinical Trials (127)

Showing 20 of 127 trialsScroll for more
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT02338232Not Applicable

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

Terminated
NCT07370506Phase 1

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Not Yet Recruiting
NCT06815497Phase 2

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

Recruiting
NCT07207057Phase 3

Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial

Recruiting
NCT06168487Phase 1

Telmisartan in Prostate Cancer

Recruiting
NCT02373163Phase 4

INTERVENCION Trial

Completed
NCT02085265Phase 2

Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

Terminated
NCT00274105Phase 4

SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients

Terminated
NCT06431477Phase 4

Efficacy and Safety of Telmisartan Compared With Losartan

Recruiting
NCT00168857Phase 4

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Completed
NCT00274599Phase 4

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Completed
NCT04510662Phase 2

Telmisartan in Respiratory Failure Due to COVID-19

Completed
NCT04354350

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

Completed
NCT04354376

Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data

Completed
NCT04736329Not Applicable

Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions

Completed
NCT05843162Phase 4

A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome

Unknown
NCT04606563Phase 3

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated
NCT02593110Not Applicable

Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease

Completed
NCT04359953Phase 3

Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
127